Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, the majority of drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
The mid-term National Action Plan on Drugs (2011-12) had, for the first time, an associated budget. This document also provided comprehensive estimates of planned, labelled and executed drug-related expenditure.
According to the national authorities, during 2011-12, planned labelled drug-related expenditure accounted for approximately 0.07 % of gross domestic product (GDP). Comparable data on executed expenditure are lacking, but the data that are available relate mainly to the funding of the health sector and indicate that public austerity affected the financing of drug-related services; there are indications that drug-related expenditure declined markedly in Greece between 2011 and 2014.